JUN 30, 2016 07:30 AM PDT
Proteome centric precision medicine: embracing pathological diversity
8 28 2851

Speakers:
  • Director, Advanced Clinical Biosystems Research Institute and Director of the Basic Science Research of the Barbra Streisand Woman's Heart Center
    Biography

      Dr. Van Eyk, Ph.D., is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. The institute mandate is to facilitate application of proteomics throughout medicine and enhance translation of new therapies and biomarkers to clinical use through the application of innovative technologies. Her research laboratory studies the underlying molecular mechanism of heart and vascular disease using a large number of proteomic methodologies focusing on the site-specific identification and quantification of disease induced post-translational modifications. The underlying concept of competitive post-translational modifications that act as molecular switches that sense and respond to dynamic changes within the cell.


      Widely regarded as an international leader in the field of proteomics, Van Eyk is best known for developing a number of lab tests to determine the presence of certain proteins or amino acids in patients' blood, which could indicate whether they have experienced a heart attack or have heart disease. She earned her Bachelor of Science degree in biology and chemistry at the University of Waterloo, Canada and her doctorate in biochemistry at the University of Alberta, Edmonton. During her directorship of the Johns Hopkins National Heart, Lung, and Blood Institute Proteomics Center, a National Heart, Lung, and Blood Institute Proteomics Center located at the Johns Hopkins University School of Medicine, Van Eyk also served as director of the Bayview Proteomics Group and as professor of medicine in the Division of Cardiology in Biological Chemistry and Biomedical Engineering. She has over 210 peer reviewed manuscripts, reviews, book chapters and has co-edited two books.


    Abstract:
    Precision medicine requires success in two intertwined aspects: precision therapy and personalized medicine. Precision therapy is being able to effectively treat the right disease; to have therapies that target for the correct pathological pathways.  Personalized medicine requires diagnosing a specific individual’s disease based on accurate assessment their complex health and pathological status. Our underlying premise is that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease. Thus, the crux of precision medicine will be the identification and precise quantification of proteins and their modified forms. We will present data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy. This concept has driven decision-making processes around new drug trials that take into account altered pathological proteomes.  Furthermore, this work has led us to consider the need for continuous patent-centric biomarker analysis at the population level. We will share our work on developing technical pipelines for health and pathological discovery and targeted proteomic analysis that reduces the barriers around gender, age and social economic status. We have begun down this path with production of system suitability and quality control measures, development of quantitative small and large multiplex assays and will discuss the remaining challenges involved and requirement for population-scale proteomics.

    Learning Objectives:
    • Understand the underlying premise that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease
    • See data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy

    Show Resources
    Loading Comments...